TY - JOUR
T1 - A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model
AU - Johansson, Anna
AU - Jones, Jonathan
AU - Pietras, Kristian
AU - Kilter, Sigrid
AU - Skytt, Asa
AU - Rudolfsson, Stina Häggström
AU - Bergh, Anders
PY - 2007/11/1
Y1 - 2007/11/1
N2 - BACKGROUND: Castration results in a major involution of the normal prostate gland. This process is initiated by effects in the prostate stroma and vasculature. Castration-induced regression of androgen sensitive prostate tumors is however less prominent and hypothetically this could be related to a limited stromal/vascular response. We therefore used animal tumor models to explore the importance of stroma and vascular effects, and if castration effects could be enhanced by a simultaneous therapy targeting the tumor stroma.METHODS: Using rats with Dunning PAP and H tumors, stereological methods, immunohistochemistry, and Western blotting, we studied the tumor response 7 and 28 days after castration and after the addition of stroma targeted therapies.RESULTS: In the normal ventral prostate (VP) nuclear androgen receptors (AR) were rapidly downregulated after castration. In contrast, the Dunning tumors downregulated the AR in the cancerous epithelium, but not in the surrounding stroma. Vascular regulators such as the angiopoietins, tie 2, and PDGF-Rbeta were not decreased in the stroma after castration, as observed in the VP, creating an environment that prevents vascular involution. When a tumor stroma targeted therapy inhibiting the tie 2 receptor and the PDGF-Rbeta simultaneously was added to castration it resulted in a decreased vascular density, increased tumor cell apoptosis and decreased tumor growth compared to castration alone.CONCLUSIONS: The stroma in highly differentiated androgen sensitive Dunning tumors is apparently androgen insensitive. If this unresponsive stroma is targeted the effects of castration can be enhanced.
AB - BACKGROUND: Castration results in a major involution of the normal prostate gland. This process is initiated by effects in the prostate stroma and vasculature. Castration-induced regression of androgen sensitive prostate tumors is however less prominent and hypothetically this could be related to a limited stromal/vascular response. We therefore used animal tumor models to explore the importance of stroma and vascular effects, and if castration effects could be enhanced by a simultaneous therapy targeting the tumor stroma.METHODS: Using rats with Dunning PAP and H tumors, stereological methods, immunohistochemistry, and Western blotting, we studied the tumor response 7 and 28 days after castration and after the addition of stroma targeted therapies.RESULTS: In the normal ventral prostate (VP) nuclear androgen receptors (AR) were rapidly downregulated after castration. In contrast, the Dunning tumors downregulated the AR in the cancerous epithelium, but not in the surrounding stroma. Vascular regulators such as the angiopoietins, tie 2, and PDGF-Rbeta were not decreased in the stroma after castration, as observed in the VP, creating an environment that prevents vascular involution. When a tumor stroma targeted therapy inhibiting the tie 2 receptor and the PDGF-Rbeta simultaneously was added to castration it resulted in a decreased vascular density, increased tumor cell apoptosis and decreased tumor growth compared to castration alone.CONCLUSIONS: The stroma in highly differentiated androgen sensitive Dunning tumors is apparently androgen insensitive. If this unresponsive stroma is targeted the effects of castration can be enhanced.
KW - Adenocarcinoma/drug therapy
KW - Androgen Receptor Antagonists
KW - Angiopoietins/antagonists & inhibitors
KW - Animals
KW - Antineoplastic Agents/pharmacology
KW - Benzamides
KW - Disease Models, Animal
KW - Down-Regulation
KW - Drug Therapy, Combination
KW - Imatinib Mesylate
KW - Immunoglobulin Fc Fragments/pharmacology
KW - Male
KW - Neoplasm Transplantation
KW - Neovascularization, Pathologic/pathology
KW - Orchiectomy
KW - Piperazines/pharmacology
KW - Prostate/blood supply
KW - Prostatic Neoplasms/drug therapy
KW - Pyrimidines/pharmacology
KW - Rats
KW - Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors
KW - Receptor, TIE-2/antagonists & inhibitors
KW - Receptors, Androgen/metabolism
KW - Recombinant Fusion Proteins/pharmacology
KW - Stromal Cells/drug effects
KW - Xenograft Model Antitumor Assays
U2 - 10.1002/pros.20657
DO - 10.1002/pros.20657
M3 - Article
C2 - 17854058
SN - 0270-4137
VL - 67
SP - 1664
EP - 1676
JO - The Prostate
JF - The Prostate
IS - 15
ER -